Why is RePreg important?
Family planning is an important topic for women with inflammatory rheumatic diseases. However, their wish for a child comes true less commonly than for healthy women. A major role here is played by questions regarding possible risks for both mother and child during pregnancy, and the safety of antirheumatic medications for the health of the child.
The systematic and prospective observation of female patients with rheumatic diseases in the SCQM RePreg Pregnancy Registry will help improve the hitherto inadequate level of data on the interactions between disease, pregnancy, antirheumatic therapy and the health of children. This can increase the long-term quality of the management of women with inflammatory rheumatic diseases before, during and after pregnancy.